Page last updated: 2024-11-05

salen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Salen (N,N'-bis(salicylidene)ethylenediamine) is a tetradentate Schiff base ligand. It is synthesized by the condensation reaction of salicylaldehyde and ethylenediamine. Salen complexes have been extensively studied due to their versatile coordination chemistry and their applications in various fields. They exhibit a wide range of applications, including catalysis, materials science, and medicine. Salen complexes are known for their catalytic activity in various organic reactions, such as oxidation, epoxidation, and asymmetric synthesis. They are also used in the development of new materials, such as sensors and molecular magnets. Additionally, salen complexes have shown promising potential in the treatment of diseases like cancer. The study of salen complexes is driven by their unique properties and their potential for technological advancements.'

disalicylaldehyde ethylenediamine: reagents for determination of iron [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID26518
CHEMBL ID594100
SCHEMBL ID247862
SCHEMBL ID711494
SCHEMBL ID22229
SCHEMBL ID372338
SCHEMBL ID18852430
MeSH IDM0057766

Synonyms (118)

Synonym
bis(salicylaldehyde)ethylenediamine
usaf do-63
phenol,2'-[1,2-ethanediylbis(nitrilomethylidyne)]bis-
1, n,n'-bis[(2-hydroxyphenyl)methylene]-
ethylenediamine,n'-disalicylidene-
.alpha.,.alpha.'-(ethylenedinitrilo)di-o-cresol
nsc2079
1,2-bis(salicylidenamino)ethane
94-93-9
o-cresol,.alpha.-ethylenediiminodi-
wln: qr b1un2nu1r bq
disalicylalethylenediamine
n,n'-disalicylidene ethylenediamine
n,n'-disalicylideneethylenediamine
o-cresol,.alpha.'-(ethylenedinitrilo)di-
n,n'-bis(salicylidene)ethylenediamine
nsc-2079
n,n'-ethylenebis(salicylideneimine)
n,n'-ethylene diimino di(o-cresol)
o-cresol, .alpha.,.alpha.'-(ethylenedinitrilo)di-
phenol, 2,2'-[1,2-ethanediylbis(nitrilomethylidyne)]bis-
2-{(e)-[(2-{[(1e)-(2-hydroxyphenyl)methylene]amino}ethyl)imino]methyl}phenol
MLS000685546
smr000312510
AH-357/03488021
2-[({2-[(2-hydroxybenzylidene)amino]ethyl}imino)methyl]phenol
brn 0535296
phenol, 2,2'-(1,2-ethanediylbis(nitrilomethylidyne))bis-
disalicylaldehyde ethylenediamine
ethylenediamine, n,n'-disalicylidene-
einecs 202-376-3
alpha,alpha'-(ethylenedinitrilo)di-o-cresol
o-cresol, alpha,alpha'-(ethylenedinitrilo)di-
disalicylidene-1,2-ethanediamine
phenol, 2,2'-(1,2-ethanediylbis(nitromethylidyne))bis-
ai3-62128
nsc 2079
alpha,alpha'-ethylenedinitrilodi-o-cresol
o-cresol, alpha,alpha-ethylenediiminodi-
1,2-ethanediamine, n,n'-bis((2-hydroxyphenyl)methylene)-
salen
2-[(e)-2-[(e)-(2-hydroxyphenyl)methyleneamino]ethyliminomethyl]phenol
rdc-0001
.alpha.,.alpha.'(ethylenedinitrilo)-di-o-cresol
n,n'-bis(salicylidene)ethylene diamino
EU-0002629
SR-01000636459-1
n,n'-bis(salicylidene)ethylenediamine, 98%
nn'-disalicylidene ethylenediamine
MAYBRIDGE1_004284
AKOS001612514
HMS553K18
CHEMBL594100
n,n'-disalicylalethylenediamine
H0199
n,n'-bis(2-hydroxybenzylidene)ethylenediamine
2,2'-((ethane-1,2-diylbis(azanylylidene))bis(methanylylidene))diphenol
A845136
NCGC00245944-01
n,n'-ethylenebis(salicylimine)
4-08-00-00196 (beilstein handbook reference)
n,n'-bis(salicylideneamino)ethane
CCG-46785
HMS2750F23
FT-0606316
FT-0606317
S10928
bis(salicylaldehyde)ethylenediimine
di(salicylidene)ethylenediamine
1,2-bis(salicylideneamino)ethane
1,6-bis(2-hydroxyphenyl)-2,5-diazahexa-1,5-diene
1,2-bis(((2-hydroxyphenyl)methylene)amino)ethane
n,n'-bis(2-hydroxybenzylidene)-1,2-ethanediamine
129409-01-4
n,n'-bis(salicylidene)ethylene-1,2-diamine
M122L9EGR6 ,
2,2-(1,2-ethanediybis((e)-nitrilomethylidyne))bisphenol
salicylaldehyde ethylenediamine bisimine
1,2-ethanedi(salicylaldimine)
salen [mi]
n,n'-bis(o-hydroxybenzylidene)ethylenediamine
SCHEMBL247862
AKOS025310499
SCHEMBL711494
bis(salicylidene)-1,2-ethylenediamine
VEUMANXWQDHAJV-UHFFFAOYSA-N
(6z)-6-[[2-[[(e)-(6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]ethylamino]methylene]cyclohexa-2,4-dien-1-one
SCHEMBL22229
DTXSID5059113
SCHEMBL372338
VEUMANXWQDHAJV-JYFOCSDGSA-N
ethylene bis(salicylimine)
2-([(2-([(2-hydroxyphenyl)methylidene]amino)ethyl)imino]methyl)phenol #
1,2-ethanediamine, n,n'-bis[(2-hydroxyphenyl)methylene]-
unii-m122l9egr6
mfcd00002244
CS-W001689
SCHEMBL18852430
bdbm50481253
n,n''''-disalicylalethylenediamine
n,n''-disalicylalethylenediamine
bis(salicylidene)ethylenediamine
AKOS027469538
(salen)
2,2-(1e,1e)-(ethane-1,2-diylbis(azan-1-yl-1-ylidene))bis(methan-1-yl-1-ylidene)diphenol
nn'-bis(salicylidene)-ethylenediamine
RQHVNNWVDLRULK-HEEUSZRZSA-N
n-undecyl mercaptan
2,2'-(1e,1'e)-(ethane-1,2-diylbis(azan-1-yl-1-ylidene))bis(methan-1-yl-1-ylidene)diphenol
salen ligand
RQHVNNWVDLRULK-XSYHWHKQSA-N
DS-17940
2-[(e)-({2-[(e)-[(2-hydroxyphenyl)methylidene]amino]ethyl}imino)methyl]phenol
(s,s)-salen
salen-
2-[2-[(2-hydroxyphenyl)methylideneamino]ethyliminomethyl]phenol
SY048524
n,n inverted exclamation mark -bis(salicylidene)ethylenediamine

Research Excerpts

Overview

Fe(Salen) is an anti-cancer compound with magnetic property. It is suitable for drug delivery and imaging.

ExcerptReferenceRelevance
"Fe(Salen) is an anti-cancer compound with magnetic property, which is suitable for drug delivery and imaging."( A magnetic anti-cancer compound for magnet-guided delivery and magnetic resonance imaging.
Amemiya, N; Aoki, I; Eguchi, H; Fukumura, H; Hirata, K; Hoshino, Y; Inoue, S; Ishikawa, Y; Kim, JH; Kurotani, R; Lee, J; Masuda, T; Sato, I; Sato, M; Singh, DJ; Tanigaki, K; Umemura, M; Urano, T; Yamamoto, M; Yoshida, K, 2015
)
0.93

Effects

ExcerptReferenceRelevance
"A Fe(salen)Cl derivative has been synthesized that remains active in monomer form."( Induction of apoptosis by Fe(salen)Cl through caspase-dependent pathway specifically in tumor cells.
Chandrashekar, TK; Chattopadhyay, S; Garai, A; Ghosh, S; Goswami, C; Kar, S; Kumar, A; Kumari, S; Maiti, PK; Meena, VS; Pradhan, N; Pratheek, BM; Singh, S, 2014
)
1.15

Actions

ExcerptReferenceRelevance
"Ti(salen) complexes catalyze the asymmetric [3 + 2] cycloaddition of cyclopropyl ketones with alkenes. "( Mechanistic Studies Inform Design of Improved Ti(salen) Catalysts for Enantioselective [3 + 2] Cycloaddition.
Jiang, B; Lin, S; Robinson, SG; Sigman, MS; Wu, X, 2020
)
1.43

Treatment

ExcerptReferenceRelevance
"Fe(salen)Cl treated tumor cells show significantly higher expression level of cytochrome c that might have triggered the cascade of reactions leading to apoptosis in cancer cells."( Induction of apoptosis by Fe(salen)Cl through caspase-dependent pathway specifically in tumor cells.
Chandrashekar, TK; Chattopadhyay, S; Garai, A; Ghosh, S; Goswami, C; Kar, S; Kumar, A; Kumari, S; Maiti, PK; Meena, VS; Pradhan, N; Pratheek, BM; Singh, S, 2014
)
1.21

Toxicity

Salen (C16H16N2O2) and salen vanadium oxide (VOS) were evaluated against chicken embryos along with chicken hepatic and fibroblastic cells. Our comparison showed that salen was a stronger teratogen than VOS.

ExcerptReferenceRelevance
"The toxic and teratogenic effects of salen (C16H16N2O2) and salen vanadium oxide (VOS) (C16H14N2O3V) were evaluated against chicken embryos along with chicken hepatic and fibroblastic cells in vitro cultures."( Comparison of toxicity and teratogenic effects of salen and vo-salen on chicken embryo.
Abdolmaleki, A; Zahri, S, 2016
)
0.96
"Our comparison showed that salen was a stronger teratogen than VOS, which may be due roles of the vanadium element, whose derivatives show physiological particulars and at low concentrations plays anticancer specifications without toxic effect."( Comparison of toxicity and teratogenic effects of salen and vo-salen on chicken embryo.
Abdolmaleki, A; Zahri, S, 2016
)
0.98
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.62280.177814.390939.8107AID2147
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.10000.100020.879379.4328AID588453
GLS proteinHomo sapiens (human)Potency25.11890.35487.935539.8107AID624170
Smad3Homo sapiens (human)Potency19.95260.00527.809829.0929AID588855
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency6.30960.707912.194339.8107AID720542
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 12Homo sapiens (human)Ki0.28000.00021.10439.9000AID1058080
Carbonic anhydrase 1Homo sapiens (human)Ki100.00000.00001.372610.0000AID1058083
Carbonic anhydrase 2Homo sapiens (human)Ki1.72000.00000.72369.9200AID1058082
Carbonic anhydrase 9Homo sapiens (human)Ki100.00000.00010.78749.9000AID1058081
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID1058081Inhibition of human recombinant carbonic anhydrase 9-mediated CO2 hydration preincubated for 15 mins by stopped-flow assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Salen and tetrahydrosalen derivatives act as effective inhibitors of the tumor-associated carbonic anhydrase XII--a new scaffold for designing isoform-selective inhibitors.
AID1058083Inhibition of human recombinant carbonic anhydrase 1-mediated CO2 hydration preincubated for 15 mins by stopped-flow assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Salen and tetrahydrosalen derivatives act as effective inhibitors of the tumor-associated carbonic anhydrase XII--a new scaffold for designing isoform-selective inhibitors.
AID1058082Inhibition of human recombinant carbonic anhydrase 2-mediated CO2 hydration preincubated for 15 mins by stopped-flow assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Salen and tetrahydrosalen derivatives act as effective inhibitors of the tumor-associated carbonic anhydrase XII--a new scaffold for designing isoform-selective inhibitors.
AID453657Inhibition of Escherichia coli Beta-ketoacyl-ACP synthase III expressed in Escherichia coli BL21 (DE3) by liquid scintillation counting2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, antibacterial activities and molecular docking studies of peptide and Schiff bases as targeted antibiotics.
AID1058080Inhibition of human recombinant carbonic anhydrase 12-mediated CO2 hydration preincubated for 15 mins by stopped-flow assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Salen and tetrahydrosalen derivatives act as effective inhibitors of the tumor-associated carbonic anhydrase XII--a new scaffold for designing isoform-selective inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (319)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.31)18.7374
1990's10 (3.13)18.2507
2000's109 (34.17)29.6817
2010's158 (49.53)24.3611
2020's41 (12.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 71.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index71.80 (24.57)
Research Supply Index5.78 (2.92)
Research Growth Index6.05 (4.65)
Search Engine Demand Index120.18 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (71.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews8 (2.48%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other315 (97.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]